154 related articles for article (PubMed ID: 24451646)
21. Fragment-based Differential Targeting of PPI Stabilizer Interfaces.
Guillory X; Wolter M; Leysen S; Neves JF; Kuusk A; Genet S; Somsen B; Morrow JK; Rivers E; van Beek L; Patel J; Goodnow R; Schoenherr H; Fuller N; Cao Q; Doveston RG; Brunsveld L; Arkin MR; Castaldi P; Boyd H; Landrieu I; Chen H; Ottmann C
J Med Chem; 2020 Jul; 63(13):6694-6707. PubMed ID: 32501690
[TBL] [Abstract][Full Text] [Related]
22. Protein-protein interactions as targets for small molecule drug discovery.
Fry DC
Biopolymers; 2006; 84(6):535-52. PubMed ID: 17009316
[TBL] [Abstract][Full Text] [Related]
23. Probing structural adaptivity at PPI interfaces with small molecules.
Wilson CG; Arkin MR
Drug Discov Today Technol; 2013 Dec; 10(4):e501-8. PubMed ID: 24451641
[TBL] [Abstract][Full Text] [Related]
24. Design of Drug-Like Protein-Protein Interaction Stabilizers Guided By Chelation-Controlled Bioactive Conformation Stabilization.
Bosica F; Andrei SA; Neves JF; Brandt P; Gunnarsson A; Landrieu I; Ottmann C; O'Mahony G
Chemistry; 2020 Jun; 26(31):7131-7139. PubMed ID: 32255539
[TBL] [Abstract][Full Text] [Related]
25. The role of protein disorder in the 14-3-3 interaction network.
Bustos DM
Mol Biosyst; 2012 Jan; 8(1):178-84. PubMed ID: 21947246
[TBL] [Abstract][Full Text] [Related]
26. Discovery of 14-3-3 PPI Stabilizers by Extension of an Amidine-Substituted Thiophene Fragment.
Wu Q; Centorrino F; Guillory X; Wolter M; Ottmann C; Cossar PJ; Brunsveld L
Chembiochem; 2024 Jan; 25(1):e202300636. PubMed ID: 37902676
[TBL] [Abstract][Full Text] [Related]
27. Stabilization of Protein-Protein Interactions in chemical biology and drug discovery.
Bier D; Thiel P; Briels J; Ottmann C
Prog Biophys Mol Biol; 2015 Oct; 119(1):10-9. PubMed ID: 26093250
[TBL] [Abstract][Full Text] [Related]
28. 14-3-3 proteins: a family of versatile molecular regulators.
Obsilová V; Silhan J; Boura E; Teisinger J; Obsil T
Physiol Res; 2008; 57 Suppl 3():S11-21. PubMed ID: 18481918
[TBL] [Abstract][Full Text] [Related]
29. Identification and structure of small-molecule stabilizers of 14-3-3 protein-protein interactions.
Rose R; Erdmann S; Bovens S; Wolf A; Rose M; Hennig S; Waldmann H; Ottmann C
Angew Chem Int Ed Engl; 2010 Jun; 49(24):4129-32. PubMed ID: 20437433
[No Abstract] [Full Text] [Related]
30. An optimised small-molecule stabiliser of the 14-3-3-PMA2 protein-protein interaction.
Richter A; Rose R; Hedberg C; Waldmann H; Ottmann C
Chemistry; 2012 May; 18(21):6520-7. PubMed ID: 22467351
[TBL] [Abstract][Full Text] [Related]
31. Peptide aptamers for small molecule drug discovery.
Bardou C; Borie C; Bickle M; Rudkin BB; Colas P
Methods Mol Biol; 2009; 535():373-88. PubMed ID: 19377984
[TBL] [Abstract][Full Text] [Related]
32. The combination of hydrogen/deuterium exchange or chemical cross-linking techniques with mass spectrometry: mapping of human 14-3-3ζ homodimer interface.
Haladová K; Mrázek H; Ječmen T; Halada P; Man P; Novák P; Chmelík J; Obšil T; Šulc M
J Struct Biol; 2012 Jul; 179(1):10-7. PubMed ID: 22580067
[TBL] [Abstract][Full Text] [Related]
33. The phytotoxin fusicoccin, a selective stabilizer of 14-3-3 interactions?
Camoni L; Visconti S; Aducci P
IUBMB Life; 2013 Jun; 65(6):513-7. PubMed ID: 23568668
[TBL] [Abstract][Full Text] [Related]
34. Discovery and structural characterization of a small molecule 14-3-3 protein-protein interaction inhibitor.
Zhao J; Du Y; Horton JR; Upadhyay AK; Lou B; Bai Y; Zhang X; Du L; Li M; Wang B; Zhang L; Barbieri JT; Khuri FR; Cheng X; Fu H
Proc Natl Acad Sci U S A; 2011 Sep; 108(39):16212-6. PubMed ID: 21908710
[TBL] [Abstract][Full Text] [Related]
35. From Tethered to Freestanding Stabilizers of 14-3-3 Protein-Protein Interactions through Fragment Linking.
Visser EJ; Jaishankar P; Sijbesma E; Pennings MAM; Vandenboorn EMF; Guillory X; Neitz RJ; Morrow J; Dutta S; Renslo AR; Brunsveld L; Arkin MR; Ottmann C
Angew Chem Int Ed Engl; 2023 Sep; 62(37):e202308004. PubMed ID: 37455289
[TBL] [Abstract][Full Text] [Related]
36. An integrative in silico approach for discovering candidates for drug-targetable protein-protein interactions in interactome data.
Sugaya N; Ikeda K; Tashiro T; Takeda S; Otomo J; Ishida Y; Shiratori A; Toyoda A; Noguchi H; Takeda T; Kuhara S; Sakaki Y; Iwayanagi T
BMC Pharmacol; 2007 Aug; 7():10. PubMed ID: 17705877
[TBL] [Abstract][Full Text] [Related]
37. Databases of protein-protein interactions and their use in drug discovery.
Fuentes G; Oyarzabal J; Rojas AM
Curr Opin Drug Discov Devel; 2009 May; 12(3):358-66. PubMed ID: 19396737
[TBL] [Abstract][Full Text] [Related]
38. A solid-phase method for synthesis of dimeric and trimeric ligands: Identification of potent bivalent ligands of 14-3-3σ.
Lee Y; Chung B; Ko D; Lim HS
Bioorg Chem; 2019 Oct; 91():103141. PubMed ID: 31377386
[TBL] [Abstract][Full Text] [Related]
39. Modulation of Protein-Protein Interactions for the Development of Novel Therapeutics.
Petta I; Lievens S; Libert C; Tavernier J; De Bosscher K
Mol Ther; 2016 Apr; 24(4):707-18. PubMed ID: 26675501
[TBL] [Abstract][Full Text] [Related]
40. PPI inhibitor and stabilizer development in human diseases.
Bosch J
Drug Discov Today Technol; 2017 Jun; 24():3-9. PubMed ID: 29233297
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
